Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Immunogenicity Study"'
Autor:
Efrem Alessandro Foglia, Tengiz Chaligava, Tamilla Aliyeva, Satenik Kharatyan, Vito Tranquillo, Carsten Pötzsch, Cornelis van Maanen, Fabrizio Rosso, Santina Grazioli, Emiliana Brocchi
Publikováno v:
Vaccines, Vol 12, Iss 3, p 295 (2024)
In countries endemic for foot-and-mouth disease (FMD), routine or emergency vaccinations are strategic tools to control the infection. According to the WOAH/FAO guidelines, a prior estimation of vaccine effectiveness is recommendable to optimize cont
Externí odkaz:
https://doaj.org/article/be52f630d73e4bccb9b923bac27b52a2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Shuang Yin, Jordan L. Pederick, Yan Sun, Yiran Qu, Yingli Wang, Bingyang Zhang, John B. Bruning, Jingxiu Bi, Anton P. J. Middelberg
Publikováno v:
Vaccine. 39:4830-4841
Human ferritin heavy chain, an example of a protein nanoparticle, has recently been used as a vaccine delivery platform. Human ferritin has advantages of uniform architecture, robust thermal and chemical stabilities, and good biocompatibility and bio
Autor:
O V Pyankov, A A Isaeva, Mariya B Borgoyakova, A. P. Rudometov, N V Danilchenko, Larisa I. Karpenko, E A Volosnikova, S V Belenkaya, L. A. Orlova, D N Shcherbakov, N V Volkova, D. E. Murashkin, D. V. Shanshin, V S Nesmeyanova, A V Zaikovskaya, Alexander A. Ilyichev, Ekaterina V Starostina
Publikováno v:
Молекулярная биология. 55:987-998
The development of preventive vaccines became the first order task in the COVID-19 pandemic caused by SARS-CoV-2. This paper reports the construction of the pVAX-RBD plasmid containing the Receptor-Binding Domain (RBD) of the S protein and a unique s
Publikováno v:
Clinical Drug Investigation. 41:29-42
INTP5 has been developed as a pegfilgrastim biosimilar. Single-dose, crossover study compared the pharmacokinetics and pharmacodynamics (PK/PD) of INTP5 (pegfilgrastim biosimilar) with reference pegfilgrastim (Neulasta®, pegfilgrastim-ref) and a mul
Autor:
Jeffrey Levy, Stuart Harris, Reginald Ewesuedo, Troy Borema, Shahrzad Moosavi, Thomas B. May, Jeffrey S. Thomas, Jeffrey Zhang, Hsuan-Ming Yao, Martin Summers
Publikováno v:
Advances in Therapy
PF-06881894 is a proposed biosimilar to pegfilgrastim (Neulasta®). This study evaluated the pharmacodynamic/pharmacokinetic (PD/PK) equivalence, immunogenicity, and safety of PF-06881894 vs pegfilgrastim reference products (US- and EU-Neulasta®) in
Autor:
A.A. Kazarov, A.M. Schuster, Olga Zalepukhina, V Yu Zorenko, M.V. Zhilyaeva, Valeria Konstantinova, Saint Petersburg City Polyclinic No. , Saint Petersburg, Russia, Dmitry Kudlay, A. V. Kim, I.A. Lavrichenko, Georgy Mishin, Nina Klimova, A.Yu. Borozinets, Tatiana Andreeva
Publikováno v:
Pediatria. Journal named after G.N. Speransky. 99:206-215
Autor:
Danniele L. Vale, Rachel B. Caligiorne, Daniel Dias, Lourena E. Costa, Miguel A. Chávez-Fumagalli, Grasiele S.V. Tavares, Abel Martínez-Rodrigo, Bethina T. Steiner, Ricardo Andrez Machado-de-Ávila, Antônio Lúcio Teixeira, Danielle F. de Magalhães-Soares, Patrícia A.F. Ribeiro, Eduardo A.F. Coelho, Daniela P. Lage, Amanda S. Machado, Fernanda F. Ramos, Julia A.G. Silveira
Publikováno v:
Diagnostic Microbiology and Infectious Disease. 95:134-143
The diagnosis of visceral leishmaniasis (VL) presents problems due to the toxicity and/or high cost of drugs. In addition, no vaccine exists to protect against human disease. In this study, the antigenicity and immunogenicity of amastin protein were
Publikováno v:
Expert opinion on biological therapy. 22(2)
BACKGROUND AND OBJECTIVE Validated and highly sensitive assays are required for comparative assessment of immunogenicity of biosimilars. For INTP5, a biosimilar pegylated filgrastim, the immunogenicity assessment included tiers that allowed for asses
Autor:
Meilin Chen, Mei Luo, Peng Liang, Cui He, Wenchang Qin, Rong Xu, Donna Ambrosino, Xinglin Li, Qiang Wang, George Siber, David M Salisbury, Joshua G. Liang, Ying Liang, Dongxia Luo, Danmei Su, Yilan Zeng, Peiwen Luo, Xiaofang Yang, Xueqin Huang, Ralf Clemens, Jinhua Wu
Beginning in late 2020, the emergence and spread of multiple variant SARS-CoV-2 strains harboring mutations which may enable immune escape necessitates the rapid evaluation of second generation COVID-19 vaccines, with the goal of inducing optimized i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c41ca75b22a079252ae8a18c07449846
https://doi.org/10.1101/2021.05.16.444369
https://doi.org/10.1101/2021.05.16.444369